M. Rinella

Most-cited papers

1. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.

   Stephen A. Harrison, P. Bedossa, Cynthia D. Guy, J. Schattenberg +25 more

   2024New England Journal of Medicine1,512 citations Open access

   Semantic Scholar

   Save

2. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.

   A. Sanyal, Philip N. Newsome, Iris Kliers, L. Østergaard +7 more

   2025New England Journal of Medicine755 citations Open access

   Semantic Scholar

   Save

3. Metabolic dysfunction-associated steatotic liver disease in adults

   Daniel Q. Huang, V. W. Wong, M. Rinella, J. Boursier +3 more

   2025Nature Reviews Disease Primers235 citations

   Semantic Scholar

   Save

4. Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients with MASH/NASH and Moderate to noncirrhotic Advanced Fibrosis.

   M. Noureddin, Michael R. Charlton, S. Harrison, M. Bansal +4 more

   2024Clinical Gastroenterology and Hepatology143 citations Open access

   Semantic Scholar

   Save

5. Semaglutide 2.4 mg in Participants With Metabolic Dysfunction‐Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial

   Philip N. Newsome, A. Sanyal, Kristiane A. Engebretsen, Iris Kliers +6 more

   2024Alimentary Pharmacology and Therapeutics135 citations Open access

   Semantic Scholar

   Save

6. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study.

   M. Israelsen, Nikolaj Torp, Stine Johansen, C. D. Hansen +12 more

   2024The Lancet Gastroenterology and Hepatology133 citations Open access

   Semantic Scholar

   Save

7. Efruxifermin in Compensated Liver Cirrhosis Caused by MASH.

   M. Noureddin, M. Rinella, N. Chalasani, Guy W. Neff +15 more

   2025New England Journal of Medicine104 citations

   Semantic Scholar

   Save

8. Noninvasive Assessment of Liver Fibrosis.

   L. Castera, M. Rinella, E. Tsochatzis

   2025New England Journal of Medicine66 citations

   Semantic Scholar

   Save

9. Implementation of a liver health check in people with type 2 diabetes.

   K. Abeysekera, L. Valenti, Z. Younossi, J. F. Dillon +24 more

   2024The Lancet Gastroenterology and Hepatology57 citations Open access

   Semantic Scholar

   Save

10. Disparities in steatosis prevalence in the United States by Race or Ethnicity according to the 2023 criteria

    L. Díaz, Jeffrey V. Lazarus, Eduardo Fuentes-López, F. Idalsoaga +18 more

    2024Communications Medicine48 citations Open access

    Semantic Scholar

    Save

11. The impact of stigma on quality of life and liver disease burden among patients with nonalcoholic fatty liver disease

    Z. Younossi, Saleh A. Alqahtani, Jesús Funuyet-Salas, M. Romero-Gómez +52 more

    2024JHEP Reports39 citations Open access

    Semantic Scholar

    Save

12. The future of International Classification of Diseases coding in steatotic liver disease: An expert panel Delphi consensus statement

    Hannes Hagström, Leon A. Adams, Alina M. Allen, C. D. Byrne +27 more

    2024Hepatology Communications38 citations Open access

    Semantic Scholar

    Save

13. Risk of hepatic and extrahepatic outcomes associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated steatotic liver disease: a systematic review and meta-analysis.

    C. Celsa, G. Pennisi, A. Tulone, G. Ciancimino +11 more

    2025The Lancet Gastroenterology and Hepatology37 citations

    Semantic Scholar

    Save

14. Phosphatidylethanol in steatotic liver disease.

    Nikolaj Torp, M. Israelsen, Maja Thiele, M. Rinella +1 more

    2025Journal of Hepatology35 citations Open access

    Semantic Scholar

    Save

15. Emerging therapies and real-world application of metabolic dysfunction-associated steatotic liver disease treatment

    Hee Yeon Kim, M. Rinella

    2025Clinical and Molecular Hepatology31 citations Open access

    Semantic Scholar

    Save

16. Effects of Resmetirom on Metabolic‐Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon‐Like Peptide‐1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO‐NASH Trial

    M. Noureddin, M. Rinella, R. Taub, D. Labriola +4 more

    2025Alimentary Pharmacology and Therapeutics30 citations Open access

    Semantic Scholar

    Save

17. Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease

    Luis Antonio Díaz, Maja Thiele, Alexandre Louvet, Brian P. Lee +26 more

    2025Nature reviews: Gastroenterology & hepatology29 citations Open access

    Semantic Scholar

    Save

18. Therapeutic targets for metabolic dysfunction-associated steatohepatitis: a personalized approach to disease management

    M. Rinella, S. Sookoian

    2026Nature reviews: Gastroenterology & hepatology24 citations

    Semantic Scholar

    Save

19. Use of non‐invasive diagnostic tools for metabolic dysfunction‐associated steatohepatitis: A qualitative exploration of challenges and barriers

    E. Tsochatzis, L. Valenti, Maja Thiele, S. Péloquin +8 more

    2024Liver international (Print)24 citations Open access

    Semantic Scholar

    Save

20. The People-First Liver Charter

    Jeffrey V. Lazarus, Dana Ivancovsky Wajcman, Silvana Pannain, Paul N. Brennan +36 more

    2025Nature Medicine21 citations Open access

    Semantic Scholar

    Save

21. An Expert Consensus Delphi Panel in MetALD: Opportunities and Challenges in Clinical Practice.

    L. A. Díaz, Veeral H. Ajmera, J. Arab, Daniel Q. Huang +24 more

    2025Clinical Gastroenterology and Hepatology21 citations

    Semantic Scholar

    Save

22. Examining the Nomenclature Change From NAFLD and NASH to MASLD and MASH.

    M. Rinella

    2023Gastroenterology & hepatology19 citations

    Semantic Scholar

    Save

23. Call to Action – Pediatric MASLD Requires Immediate Attention to Curb Health Crisis

    P. Hartmann, M. Mouzaki, S. Hassan, M. Kehar +23 more

    2025Hepatology13 citations

    Semantic Scholar

    Save

24. Low HDL cholesterol levels in women and hypertriglyceridemia in men: predictors of MASLD onset in individuals without steatosis

    Tsubasa Tsutsumi, T. Kawaguchi, Hideki Fujii, Yoshihiro Kamada +30 more

    2025Journal of gastroenterology12 citations

    Semantic Scholar

    Save

25. Steatotic liver disease: a new name to reflect the combined role of alcohol and metabolic dysfunction

    A. Krag, M. Rinella

    2024Nature Medicine11 citations

    Semantic Scholar

    Save

26. Phase 3 ESSENCE Trial: Semaglutide in metabolic dysfunction-associated steatohepatitis (MASH)

    H. Bajaj, Philip N. Newsome, Arun J. Sanyal, Iris Kliers +8 more

    2025Canadian Journal of Diabetes8 citations

    Semantic Scholar

    Save

27. Awareness of metabolic dysfunction–associated steatotic liver disease (MASLD) in 4 major cities in the United States

    Jeffrey V. Lazarus, Trenton M. White, Alina M. Allen, Silvana Pannain +13 more

    2025Hepatology Communications8 citations Open access

    Semantic Scholar

    Save

28. Fecal Butyrate and Deoxycholic Acid Concentrations Correlate With Mortality in Patients With Liver Disease

    M. Odenwald, R. Ramaswamy, Huaiying Lin, C. Lehmann +22 more

    2025Gastro Hep Advances8 citations Open access

    Semantic Scholar

    Save

29. A call to action from the Global Think-tank on Steatotic Liver Disease

    Jeffrey V. Lazarus, Henry E. Mark, Trenton M White, Leire Agirre-Garrido +21 more

    2026Nature Health7 citations

    Semantic Scholar

    Save

30. Aspirin Use and Mediterranean Diet Adherence as Factors Associated With Overall Mortality in Patients With MASLD in NHANES

    Tsubasa Tsutsumi, M. Charlton, V. Oddo, Sarah Vilt +6 more

    2025Hepatology Research4 citations

    Semantic Scholar

    Save

31. MASLD as a complication of obesity must include liver risk stratification

    M. Rinella, A. Sanyal, R. Loomba, M. Noureddin +3 more

    2026Nature Medicine3 citations

    Semantic Scholar

    Save

32. The dynamic spectrum of steatotic liver disease: the global perspective.

    Z. Younossi, S. Zelber-Sagi, Markos Kalligeros, Dana Ivancovsky Wajcman +27 more

    2026Nature reviews: Gastroenterology & hepatology3 citations

    Semantic Scholar

    Save

33. Awareness of metabolic dysfunction-associated steatotic liver disease (MASLD) among primary care providers in the four most populous U.S. cities.

    Jeffrey V. Lazarus, Trenton M. White, Melina I. Manolas, Alina M. Allen +13 more

    2026Annals of Hepatology3 citations Open access

    Semantic Scholar

    Save

34. Comparative efficacy of phase 2-3 therapies for non-cirrhotic metabolic dysfunction-associated steatohepatitis: An updated network meta-analysis.

    Tsubasa Tsutsumi, N. S. Tang, Cheng H. Ng, Hiroyuki Suzuki +25 more

    2026i Medicina3 citations Open access

    Semantic Scholar

    Save

35. GS-012 Efruxifermin improves fibrosis in participants with compensated cirrhosis due to MASH: results of a 96-week, randomized, doubleblind, placebo-controlled, phase 2b trial (SYMMETRY)

    M. Noureddin, M. Rinella, N. Chalasani, Guy W. Neff +15 more

    2025Journal of Hepatology3 citations

    Semantic Scholar

    Save

36. Reconciling diagnostic definitions for proposing metabolic dysfunction-associated steatotic liver disease in chronic kidney disease risk

    Tsubasa Tsutsumi, Takumi Kawaguchi, Hiroyuki Suzuki, R. Hashida +3 more

    2025Hepatobiliary surgery and nutrition3 citations Open access

    Semantic Scholar

    Save

37. Body composition and muscle composition phenotypes in patients on waitlist and shortly after liver transplant – results from a pilot study

    Mikael F. Forsgren, Stewart Pine, Claire Harrington, Dyanna Gregory +4 more

    2024BMC Gastroenterology3 citations Open access

    Semantic Scholar

    Save

38. The new hepatic steatosis nomenclature. No more NAFLD!

    G. Castro-Narro, M. Rinella

    2024Revista de Gastroenterología de México3 citations Open access

    Semantic Scholar

    Save

39. Reply to: "From NAFLD to MASLD: Promise and pitfalls of a new definition": EASL, AASLD and ALEH stand united to advance the field of steatotic liver disease.

    M. Rinella, Graciela E. Castro-Narro, A. Krag, N. Terrault +1 more

    2023Journal of Hepatology3 citations

    Semantic Scholar

    Save

40. Clinical Outcomes and Non‐Invasive Testing in Metabolic Dysfunction‐Associated Steatohepatitis With Cirrhosis: A Systematic Review

    Hannes Hagström, C. Hellmund, Jeffrey V. Lazarus, Riku Ota +5 more

    2026Liver international (Print)2 citations Open access

    Semantic Scholar

    Save

41. The Relentless Progression of Metabolic Dysfunction-associated Steatotic Liver Disease in Liver Transplantation in Spain.

    Laura Martínez-Arenas, Â. Carvalho-Gomes, Enrique Vidal, Danielle Brandman +12 more

    2025Transplantation2 citations Open access

    Semantic Scholar

    Save

42. P1 Phase 3 ESSENCE trial evaluating semaglutide in metabolic dysfunction-associated steatohepatitis (MASH): part 1 results and secondary analysis

    Philip N. Newsome, Arun J. Sanyal, Iris Kliers, L. Østergaard +17 more

    2025P1 Phase 3 ESSENCE trial evaluating semaglutide in metabolic dysfunction-associated steatohepatitis (MASH): part 1 results and secondary analysis2 citations

    Semantic Scholar

    Save

43. Real-world work productivity is impaired in people with metabolic dysfunction-associated steatotic liver disease in the USA

    Shraddha Shinde, M. Rinella, M. Hartman, D. Schapiro +4 more

    2025JHEP Reports2 citations Open access

    Semantic Scholar

    Save

44. Practical Considerations for the use of Semaglutide in MASH.

    M. Odenwald, M. Rinella

    2025American Journal of Gastroenterology2 citations

    Semantic Scholar

    Save

45. LBP-020 A global Delphi consensus to define chronic liver disease severity: replacing cirrhosis with a stage-based model

    A. Krag, Nikolaj Torp, Stine Johansen, Emmanuel A. Tsochatzis +7 more

    2026Journal of Hepatology1 citations

    Semantic Scholar

    Save

46. The Economic Burden of Metabolic Dysfunction‐Associated Steatohepatitis (MASH) With Cirrhosis: A Systematic Review

    Jeffrey V. Lazarus, C. Freeman, Hannes Hagström, M. Noureddin +5 more

    2026Liver International Communications1 citations Open access

    Semantic Scholar

    Save

47. Author Correction: The dynamic spectrum of steatotic liver disease: the global perspective.

    Z. Younossi, S. Zelber-Sagi, Markos Kalligeros, Dana Ivancovsky Wajcman +27 more

    2026Nature reviews: Gastroenterology & hepatology1 citations Open access

    Semantic Scholar

    Save

48. Determining Cirrhosis Status in Candidates for Resmetirom.

    M. Noureddin, M. Bansal, M. Rinella

    2025Clinical Gastroenterology and Hepatology1 citations

    Semantic Scholar

    Save

49. FRI-208 qBallooning: AI-based ballooned hepatocyte detection and quantification by second harmonic generation/two photon excitation microscopy

    David E. Kleiner, A. Clouston, Zachary Goodman, Cynthia D. Guy +19 more

    2024Journal of Hepatology1 citations

    Semantic Scholar

    Save

50. La nueva nomenclatura de esteatosis hepática. ¡No más NAFLD!

    G. Castro-Narro, M. Rinella

    2024Revista de Gastroenterología de México1 citations Open access

    Semantic Scholar

    Save